← All trials
NCT04859751
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Dec 31, 2023
- First posted
- Apr 26, 2021
- Last posted
- Apr 26, 2021
- Enrollment
- 53
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.